We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
+$7.44M
Cap. Flow %
5.12%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$6.93M
2
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.78M
3
UNH icon
UnitedHealth
UNH
+$3.65M
4
CVS icon
CVS Health
CVS
+$3.53M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 48.9%
2 Financials 13.82%
3 Miscellaneous 11.7%
4 Technology 6.61%
5 Consumer Discretionary 5.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
126
DELISTED
Catalyst Pharmaceutical
CPRX
$225K 0.15%
+11,441
New +$235K
UPB
127
CALL
Upstream Bio Inc
UPB
$329M
$220K 0.15%
+462
New +$7.18K
RVPH
128
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$219K 0.15%
29,695
-2,364
-7% -$20.1K
RARE icon
129
PUT
Ultragenyx Pharmaceutical
RARE
$1.51B
$215K 0.15%
320
-27,712
-99% -$831K
SGRY icon
130
Surgery Partners
SGRY
$1.87B
$210K 0.14%
+9,704
New +$216K
ARCT icon
131
Arcturus Therapeutics
ARCT
$450M
$206K 0.14%
+11,189
New +$180K
GOSS icon
132
CALL
Gossamer Bio
GOSS
$85.7M
$203K 0.14%
1,929
– –
CRSP icon
133
CALL
CRISPR Therapeutics
CRSP
$5.39B
$192K 0.13%
258
– –
HOOD icon
134
CALL
Robinhood
HOOD
$110B
$188K 0.13%
157
-246
-61% -$26.8K
TRVI icon
135
Trevi Therapeutics
TRVI
$2.46B
$180K 0.12%
19,688
-23,100
-54% -$173K
TERN
136
CALL
DELISTED
Terns Pharmaceuticals
TERN
$174K 0.12%
520
+147
+39% +$939
ABUS icon
137
CALL
Arbutus Biopharma
ABUS
$1.02B
$171K 0.12%
+1,192
New +$4.38K
ZYME icon
138
CALL
Zymeworks
ZYME
$2.09B
$171K 0.12%
451
+33
+8% +$472
MREO
139
CALL
Mereo BioPharma
MREO
$39.9M
$169K 0.12%
3,501
+466
+15% +$859
IONS icon
140
CALL
Ionis Pharmaceuticals
IONS
$9.65B
$165K 0.11%
+229
New +$11.2K
OCUL icon
141
CALL
Ocular Therapeutix
OCUL
$2.34B
$164K 0.11%
313
– –
NKE icon
142
Nike
NKE
$57B
$162K 0.11%
+2,325
New +$173K
NVO
143
PUT
Novo Nordisk
NVO
$206B
$159K 0.11%
+229
New +$13.4K
FSLR icon
144
First Solar
FSLR
$22B
$154K 0.11%
+700
New +$134K
QURE icon
145
PUT
uniQure
QURE
$3.09B
$147K 0.1%
+688
New +$12.5K
HRMY icon
146
PUT
Harmony Biosciences
HRMY
$2.46B
$143K 0.1%
+115
New +$3.96K
XERS icon
147
Xeris Biopharma Holdings
XERS
$1.56B
$140K 0.1%
+17,202
New +$114K
CTMX icon
148
CytomX Therapeutics
CTMX
$808M
$136K 0.09%
+42,645
New +$96K
COGT icon
149
CALL
Cogent Biosciences
COGT
$6.03B
$133K 0.09%
460
+444
+2,775% +$5.26K
TIGR
150
UP Fintech Holding
TIGR
$914M
$125K 0.09%
+11,688
New +$125K
4 5
6
7 8

Similar funds

JWM
Jessup Wealth Management Dayton, Ohio $335M AUM 56.2% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $335M AUM 97.32% 1-Year Est. Return
TFA
TPG Financial Advisors Portland, Oregon $335M AUM 14.14% 1-Year Est. Return
SIM
Seaview Investment Managers Miami, Florida $335M AUM 47.2% 1-Year Est. Return
OWM
OneAscent Wealth Management Birmingham, Alabama $336M AUM 20.38% 1-Year Est. Return
SS
Spinecap SAS Paris, France $335M AUM 16.94% 1-Year Est. Return
BIA
BHK Investment Advisors Birmingham, Alabama $335M AUM 20.89% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners deployed $7.44M of net new capital in Q3 2025, opening 137 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 229,544 shares worth $8.19M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was iShares Bitcoin Trust, an estimated $3.43M trimmed.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.